DENVER, March 18, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress.Date/Time: Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT   Webcast: The live webcast and replay can be found here.   Register for the call: Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration.   A replay of the call will be available after...

Record Full Year Revenues, Processing Volume (up 19%) and Transactions Processed (up 30%) SAN ANTONIO, March 18, 2026 (GLOBE NEWSWIRE) — Usio, Inc. (“Usio” or the “Company”) (Nasdaq: USIO), a leading Fintech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced financial results for the fourth quarter and year ended December 31, 2025. Louis Hoch, Chairman and Chief Executive Officer of Usio, said, “I am pleased to report another year of positive Adjusted EBITDA1 and Cash Flow from Operations on solid revenue growth. In addition, we increased total processing volume to $8.4 billion, up 19% compared to 2024. As anticipated, the second half of the year was much improved from the first half, especially the fourth quarter, where...

Record results and outlook reflect strategic value of memory in AI era BOISE, Idaho, March 18, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced results for its second quarter of fiscal 2026, which ended February 26, 2026. Fiscal Q2 2026 highlightsRevenue of $23.86 billion versus $13.64 billion for the prior quarter and $8.05 billion for the same period last year GAAP net income of $13.79 billion, or $12.07 per diluted share Non-GAAP net income of $14.02 billion, or $12.20 per diluted share Operating cash flow of $11.90 billion versus $8.41 billion for the prior quarter and $3.94 billion for the same period last year“Micron set new records across revenue, gross margin, EPS, and free cash flow in fiscal Q2, driven by a strong demand environment, tight industry supply, and our strong execution,...

MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 HighlightsTotal revenue of $49.1 million, a 40% increase year-over-year Gross margin of 79.5%, non-GAAP gross margin of 79.9% Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 million U.S. installed base of 1,465 accounts as of December 31, 2025 U.S. Plaque installed base of 489 accounts as of December 31, 2025 Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives for Plaque to approximately 75%2026 Annual GuidanceTotal revenue of $218 million to $222 million (approximately 24% to 26% growth year-over-year) Non-GAAP...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint Presented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASN Ended 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported...

PRESS RELEASE        Paris, 18 March 2026 – 5:45pm YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION 2025 RESULTS Positive net income in an unstable geopolitical and economic environmentTurnover1 of €156.1m, down -5.4% Operating EBITDA2 : €52.7m Group share of net profit: €1.7m, vs. €3.9m in 2024“Despite significant economic and geopolitical tensions in 2025, the TOUAX Group confirmed the resilience of its business model and its adaptability. Outside Europe, demand for mobile assets linked to transport infrastructure remains strong. With a diversified offer, long-term leasing contracts and a strong presence in various complementary business segments, the Group benefits from recurring revenue enabling it to face difficult economic conditions while limiting volatility. The strong momentum in management activity on...

LiveWorld continues to increase its AI investment CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025. Twelve Months 2025 Financial and Business HighlightsTotal twelve-month revenues of $11.1 million Healthcare revenues of $10 million in 2025 Net income from operations of $326,000 Net Cash of $5.7 millionManagement Commentary “We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI...

Q4 gross margins increased quarterly despite revenue dip2025 Revenue by Process Node and ApplicationsOn a technology basis, 87% of Alchip’s 2025 revenue came through process technologies at 7nm or smaller line widths. On an application basis, HPC accounted for 83% of Alchip’s 2025 revenue.Taipei, Taiwan, March 18, 2026 (GLOBE NEWSWIRE) — Alchip Technologies reported fourth‑quarter performance, with gross margin and net profit exceeding internal expectations. At the same time, the company reported a dip in 2025 revenue, citing limited production; but forecast a return to long-term growth in 2026. Alchip reported 2025 fourth quarter net income of $48 million, up 8.1 percent over third quarter 2025 net income of $44.3 million.  Fourth quarter 2025 revenue was $152.7 million, compared to fourth quarter 2024 revenue of $404.1...

2025 Net Loss of $5,025,000 ($1.51 loss per share) vs. Net Loss of $646,000 ($0.19 loss per share) in 2024 2025 EBITDA, As Adjusted, was a loss of $3,971,000 ($1.19 loss per share) vs. earnings of $159,000 ($0.05 per diluted share) in 2024 Fourth Quarter 2025 Net Loss of $708,000 ($0.21 loss per share) vs. Net Loss of $252,000 ($0.08 loss per share) in Prior Year Period Fourth Quarter 2025 EBITDA, As Adjusted, was a loss of $465,000 ($0.14 loss per share) vs. earnings of $383,000 ($0.11 per diluted share) in Prior Year Period Backlog at December 31, 2025 was approximately $12.2 million compared to approximately $12.0 million at December 31, 2024 HAUPPAUGE, N.Y., March 18, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (OTCID Basic Market:ORBT) today announced results for the fourth quarter and the year ended December 31, 2025. Fourth...

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key HighlightsIn December 2025, the Company announced the results of an interim analysis of the Halneuron® Phase 2b trial. The independent statistical review committee...